Could a Parkinson's drug help Depression-Related lack of motivation?

NCT ID NCT05909267

Recruiting now Knowledge-focused Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a single dose of L-dopa, a drug used for Parkinson's, can improve motivation and motor function in people with major depression who have signs of low-grade inflammation. Researchers will compare L-dopa to a placebo in 165 participants (patients and healthy controls) using tasks that measure reward-seeking and walking speed. The goal is to understand if inflammation-related dopamine changes contribute to symptoms like anhedonia and sluggishness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L-dopa/Carbidopa
What this could lead to: If successful, this study could point toward a treatment for motivation and movement problems in depression linked to inflammation.
What could go wrong: This is an early-stage study with a single dose, not a treatment trial. Results may not lead to a new therapy, and L-dopa can cause side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia Depression Inflammation major depressive disorder Psychomotor Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, MAJOR

Contacts and locations

Locations

Klinik für Psychiatrie und Psychotherapie
RECRUITING

Steglitz, 12203, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.